GP
Therapeutic Areas
ProQR Pipeline
| Drug | Indication | Phase |
|---|---|---|
| QR-4210 (sepofarsen) | Usher syndrome type 2A / Retinitis Pigmentosa (USH2A exon 13 mutations) | Phase 2/3 |
| QR-1123 | Autosomal Dominant Retinitis Pigmentosa (adRP) caused by P23H mutation in RHO gene | Phase 1/2 |
| QR-504a | Fuchs Endothelial Corneal Dystrophy (FECD) | Preclinical |
| Axiomer® Liver Candidate(s) | Undisclosed genetic liver disorders | Discovery/Preclinical |
| Axiomer® CNS Candidate(s) | Undisclosed genetic CNS disorders | Discovery/Preclinical |
Leadership Team at ProQR
DA
Daniel A. de Boer
Founder & Chief Executive Officer
SS
Smital Shah
Chief Business Officer
LX
Lucas X. van der Meer
Chief Financial Officer
DA
David A. Rodman, M.D.
Chief Medical Officer
K(
Katherine (Kate) R. High, M.D.
Chair of the Scientific Advisory Board
AG
Aniz Girach, M.D.
Chief Development Officer (Ophthalmology)
DO
Dónal O'Keeffe
Senior Vice President, Technical Operations
BG
Brigitte G. M. D. de Greef
Chair of the Supervisory Board
SB
Susan B. Dillon, Ph.D.
Member of the Supervisory Board
BV
Benno van Dongen
Member of the Supervisory Board